{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:20:05Z","timestamp":1792448405389,"version":"4.5.0"},"reference-count":247,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2017SF-1955"],"award-info":[{"award-number":["TMA2017SF-1955"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although combination antiretroviral therapy (ART) has reduced mortality and improved lifespan for people living with HIV, it does not provide a cure. Patients must be on ART for the rest of their lives and contend with side effects, unsustainable costs, and the development of drug resistance. A cure for HIV is, therefore, warranted to avoid the limitations of the current therapy and restore full health. However, this cure is difficult to find due to the persistence of latently infected HIV cellular reservoirs during suppressive ART. Approaches to HIV cure being investigated include boosting the host immune system, genetic approaches to disable co-receptors and the viral genome, purging cells harboring latent HIV with latency-reversing latency agents (LRAs) (shock and kill), intensifying ART as a cure, preventing replication of latent proviruses (block and lock) and boosting T cell turnover to reduce HIV-1 reservoirs (rinse and replace). Since most people living with HIV are in Africa, methods being developed for a cure must be amenable to clinical trials and deployment on the continent. This review discusses the current approaches to HIV cure and comments on their appropriateness for Africa.<\/jats:p>","DOI":"10.1007\/s00018-022-04421-z","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T17:03:10Z","timestamp":1657126990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["HIV cure strategies: which ones are appropriate for Africa?"],"prefix":"10.1007","volume":"79","author":[{"given":"Christopher Zaab-Yen","family":"Abana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Lamptey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn Y.","family":"Bonney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-4656","authenticated-orcid":false,"given":"George B.","family":"Kyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"4421_CR1","unstructured":"UNAIDS\/WHO estimates (2020) Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic. Accessed: Dec 10, 2021. https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"issue":"2","key":"4421_CR2","first-page":"80","volume":"23","author":"J Ananworanich","year":"2015","unstructured":"Ananworanich J (2015) What will it take to cure HIV? Topics Antiviral Med 23(2):80\u201384","journal-title":"Topics Antiviral Med"},{"issue":"1","key":"4421_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.virol.2014.02.021","volume":"454\u2013455","author":"CP Passaes","year":"2014","unstructured":"Passaes CP, S\u00e1ez-Ciri\u00f3n A (2014) HIV cure research: advances and prospects. Virology 454\u2013455(1):340\u2013352. https:\/\/doi.org\/10.1016\/j.virol.2014.02.021 (Academic Press Inc.)","journal-title":"Virology"},{"issue":"7","key":"4421_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nm.4113","volume":"22","author":"R Banga","year":"2016","unstructured":"Banga R et al (2016) PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med 22(7):754\u2013761. https:\/\/doi.org\/10.1038\/nm.4113","journal-title":"Nat Med"},{"issue":"2","key":"4421_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nm.3781","volume":"21","author":"Y Fukazawa","year":"2015","unstructured":"Fukazawa Y et al (2015) B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 21(2):132\u2013139. https:\/\/doi.org\/10.1038\/nm.3781","journal-title":"Nat Med"},{"issue":"24","key":"4421_CR6","doi-asserted-by":"publisher","first-page":"13193","DOI":"10.1073\/pnas.94.24.13193","volume":"94","author":"TW Chun","year":"1997","unstructured":"Chun TW et al (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94(24):13193\u201313197. https:\/\/doi.org\/10.1073\/pnas.94.24.13193","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5341","key":"4421_CR7","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","volume":"278","author":"D Finzi","year":"1997","unstructured":"Finzi D et al (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1979) 278(5341):1295\u20131300. https:\/\/doi.org\/10.1126\/science.278.5341.1295","journal-title":"Science (1979)"},{"key":"4421_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/NM880","author":"S Jd","year":"2003","unstructured":"Jd S et al (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. https:\/\/doi.org\/10.1038\/NM880","journal-title":"Nat Med"},{"issue":"8","key":"4421_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","volume":"15","author":"N Chomont","year":"2009","unstructured":"Chomont N et al (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15(8):893\u2013900. https:\/\/doi.org\/10.1038\/nm.1972","journal-title":"Nat Med"},{"issue":"2","key":"4421_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nm.3445","volume":"20","author":"MJ Buzon","year":"2014","unstructured":"Buzon MJ et al (2014) HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med 20(2):139\u2013142. https:\/\/doi.org\/10.1038\/nm.3445","journal-title":"Nat Med"},{"issue":"10","key":"4421_CR11","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20061496","volume":"203","author":"C Petrovas","year":"2006","unstructured":"Petrovas C et al (2006) PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 203(10):2281\u20132292. https:\/\/doi.org\/10.1084\/jem.20061496","journal-title":"J Exp Med"},{"issue":"10","key":"4421_CR12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann L et al (2006) Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 12(10):1198\u20131202. https:\/\/doi.org\/10.1038\/nm1482","journal-title":"Nat Med"},{"issue":"11","key":"4421_CR13","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.4049\/jimmunol.178.11.6975","volume":"178","author":"E Connick","year":"2007","unstructured":"Connick E et al (2007) CTL Fail to Accumulate at Sites of HIV-1 Replication in Lymphoid Tissue. J Immunol 178(11):6975\u20136983. https:\/\/doi.org\/10.4049\/jimmunol.178.11.6975","journal-title":"J Immunol"},{"issue":"11","key":"4421_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1001907","volume":"12","author":"A Dutta","year":"2015","unstructured":"Dutta A, Barker C, Kallarakal A (2015) The HIV treatment gap: estimates of the financial resources needed versus available for scale-up of antiretroviral therapy in 97 countries from 2015 to 2020. PLoS Med 12(11):e1001907. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1001907","journal-title":"PLoS Med"},{"key":"4421_CR15","unstructured":"Joint United Nations Programme on HIV\/AIDS, \u201cJoint United Nations Programme on HIV\/AIDS. The Gap Report,\u201d Geneva, 2014. Accessed: May 23, 2022. https:\/\/www.unaids.org\/en\/resources\/documents\/2014\/20140716_UNAIDS_gap_report"},{"key":"4421_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2016.02.001","volume":"18","author":"AR Cillo","year":"2016","unstructured":"Cillo AR, Mellors JW (2016) Which therapeutic strategy will achieve a cure for HIV-1? Curr Opin Virol 18:14\u201319. https:\/\/doi.org\/10.1016\/j.coviro.2016.02.001","journal-title":"Curr Opin Virol"},{"issue":"4","key":"4421_CR17","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/v6041715","volume":"6","author":"A Battistini","year":"2014","unstructured":"Battistini A, Sgarbanti M (2014) HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses 6(4):1715\u20131758. https:\/\/doi.org\/10.3390\/v6041715 (MDPI AG)","journal-title":"Viruses"},{"key":"4421_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev-pharmtox-010510-100237","volume":"51","author":"SK Choudhary","year":"2011","unstructured":"Choudhary SK, Margolis DM (2011) Curing HIV: pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol 51:397\u2013418. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010510-100237","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"4421_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12981-017-0157-8","volume":"14","author":"A Kwarteng","year":"2017","unstructured":"Kwarteng A, Ahuno ST, Kwakye-Nuako G (2017) The therapeutic landscape of HIV-1 via genome editing. AIDS Res Ther 14(1):32. https:\/\/doi.org\/10.1186\/s12981-017-0157-8","journal-title":"AIDS Res Ther"},{"issue":"1","key":"4421_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-018-0451-0","volume":"15","author":"C M\u00e9ndez","year":"2018","unstructured":"M\u00e9ndez C, Ledger S, Petoumenos K, Ahlenstiel C, Kelleher AD (2018) RNA-induced epigenetic silencing inhibits HIV-1 reactivation from latency. Retrovirology 15(1):1\u201318. https:\/\/doi.org\/10.1186\/s12977-018-0451-0","journal-title":"Retrovirology"},{"issue":"4","key":"4421_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00465-15","volume":"6","author":"G Mousseau","year":"2015","unstructured":"Mousseau G, Kessing CF, Fromentin R, Trautmann L, Chomont N, Valente ST (2015) The tat inhibitor didehydro-cortistatin a prevents HIV-1 reactivation from latency. MBio 6(4):1\u201314. https:\/\/doi.org\/10.1128\/mBio.00465-15","journal-title":"MBio"},{"key":"4421_CR22","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.79669","author":"K Ognenovska","year":"2019","unstructured":"Ognenovska K et al (2019) Mechanisms for controlling HIV-1 infection: a gene therapy approach. In Vivo Ex Vivo Gene Ther Inherited Non-Inherited Disord. https:\/\/doi.org\/10.5772\/intechopen.79669","journal-title":"In Vivo Ex Vivo Gene Ther Inherited Non-Inherited Disord"},{"issue":"6","key":"4421_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.01423-18","volume":"9","author":"GB Kyei","year":"2018","unstructured":"Kyei GB et al (2018) Splicing factor 3B subunit 1 interacts with HIV tat and plays a role in viral transcription and reactivation from latency. MBio 9(6):1\u201314. https:\/\/doi.org\/10.1128\/mBio.01423-18","journal-title":"MBio"},{"issue":"6","key":"4421_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/J.IT.2020.04.003","volume":"41","author":"Z Grossman","year":"2020","unstructured":"Grossman Z et al (2020) \u2018Rinse and replace\u2019: boosting T cell turnover to reduce HIV-1 reservoirs. Trends Immunol 41(6):466\u2013480. https:\/\/doi.org\/10.1016\/J.IT.2020.04.003","journal-title":"Trends Immunol"},{"issue":"4599","key":"4421_CR25","first-page":"868","volume":"220","author":"JC Barr\u00e9-Sinoussi","year":"1983","unstructured":"Barr\u00e9-Sinoussi JC, Chermann F, Rey F, Nugeyre MT, Chamaret S, Gruest J, Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1979) 220(4599):868\u2013871","journal-title":"Science (1979)"},{"key":"4421_CR26","doi-asserted-by":"crossref","unstructured":"H\u00fctter G et al (2009) Long-term control of HIV by CCR5 Delta32\/ Delta32 stem-cell transplantation","DOI":"10.1016\/S0084-3873(09)79612-9"},{"issue":"25","key":"4421_CR27","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1056\/NEJMc1412279","volume":"371","author":"A Abbate","year":"2014","unstructured":"Abbate A, Gold KJ, Goldman JWEBD, Kathryn L, Moseley MPH (2014) More on shift of HIV tropism in stem-cell transplantation with CCR5 Delta32\/Delta32 mutation. N Engl J Med 371(25):2437\u20132438. https:\/\/doi.org\/10.1056\/NEJMc1412279","journal-title":"N Engl J Med"},{"issue":"9","key":"4421_CR28","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1056\/NEJMc1405805","volume":"371","author":"L Kordelas","year":"2014","unstructured":"Kordelas L, Verheyen J, Esser S (2014) Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med 371(9):880\u2013882. https:\/\/doi.org\/10.1056\/NEJMc1405805","journal-title":"N Engl J Med"},{"issue":"5","key":"4421_CR29","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","volume":"7","author":"RK Gupta","year":"2020","unstructured":"Gupta RK et al (2020) Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. The Lancet HIV 7(5):e340\u2013e347. https:\/\/doi.org\/10.1016\/S2352-3018(20)30069-2","journal-title":"The Lancet HIV"},{"issue":"19","key":"4421_CR30","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1056\/nejmoa1302976","volume":"369","author":"D Persaud","year":"2013","unstructured":"Persaud D et al (2013) Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 369(19):1828\u20131835. https:\/\/doi.org\/10.1056\/nejmoa1302976","journal-title":"N Engl J Med"},{"issue":"8","key":"4421_CR31","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/nejmc1413931","volume":"372","author":"K Luzuriaga","year":"2015","unstructured":"Luzuriaga K et al (2015) Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med 372(8):786\u2013788. https:\/\/doi.org\/10.1056\/nejmc1413931","journal-title":"N Engl J Med"},{"key":"4421_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003211","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013","unstructured":"S\u00e1ez-Ciri\u00f3n A et al (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1003211","journal-title":"PLoS Pathog"},{"issue":"4","key":"4421_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/archinte.1960.03820040061007","volume":"106","author":"JW Ferrebee","year":"1960","unstructured":"Ferrebee JW, Thomas ED (1960) Transplantation of marrow in man. Arch Intern Med 106(4):523\u2013531. https:\/\/doi.org\/10.1001\/archinte.1960.03820040061007","journal-title":"Arch Intern Med"},{"issue":"11","key":"4421_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1056\/NEJM198309153091114","volume":"309","author":"J Hassett","year":"1983","unstructured":"Hassett J, Zaroulis C, Greenberg M, Fiegal F (1983) Bone-marrow transplantation in AIDS. N Engl J Med 309(11):665\u2013665. https:\/\/doi.org\/10.1056\/NEJM198309153091114","journal-title":"N Engl J Med"},{"issue":"3","key":"4421_CR35","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.v71.3.666.666","volume":"71","author":"LF Verdonck","year":"1988","unstructured":"Verdonck LF, De Gast GC, Lange JMA, Schuurman HJ, Dekker AW, Bast BJEG (1988) Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation. Blood 71(3):666\u2013671. https:\/\/doi.org\/10.1182\/blood.v71.3.666.666","journal-title":"Blood"},{"issue":"5","key":"4421_CR36","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/BF01964248","volume":"7","author":"G Furlini","year":"1988","unstructured":"Furlini G, Re MC, Bandini G, Albertazzi L, La Placa M (1988) Antibody response to human immunodeficiency virus after infected bone marrow transplant. Eur J Clin Microbiol Infect Dis 7(5):664\u2013666. https:\/\/doi.org\/10.1007\/BF01964248","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"17","key":"4421_CR37","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/nejm198410253111706","volume":"311","author":"HC Lane","year":"1984","unstructured":"Lane HC et al (1984) Partial immune reconstitution in a patient with the acquired immunodeficiency syndrome. N Engl J Med 311(17):1099\u20131103. https:\/\/doi.org\/10.1056\/nejm198410253111706","journal-title":"N Engl J Med"},{"issue":"1","key":"4421_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/00007890-198707000-00007","volume":"44","author":"E Vilmer","year":"1987","unstructured":"Vilmer E et al (1987) Clinical and immunological restoration in patients with aids after marrow transplantation, using lymphocyte transfusions from the marrow donor. Transplantation 44(1):25\u201329. https:\/\/doi.org\/10.1097\/00007890-198707000-00007","journal-title":"Transplantation"},{"issue":"November 2018","key":"4421_CR39","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2019.03.008","volume":"166","author":"E Abner","year":"2019","unstructured":"Abner E, Jordan A (2019) HIV \u2018shock and kill\u2019 therapy: in need of revision. Antiviral Res 166(November 2018):19\u201334. https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.008","journal-title":"Antiviral Res"},{"issue":"6","key":"4421_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/9498","volume":"5","author":"TW Chun","year":"1999","unstructured":"Chun TW et al (1999) Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 5(6):651\u2013655. https:\/\/doi.org\/10.1038\/9498","journal-title":"Nat Med"},{"issue":"17","key":"4421_CR41","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1097\/00002030-199912030-00012","volume":"13","author":"JM Prins","year":"1999","unstructured":"Prins JM et al (1999) Immune-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 13(17):2405\u20132410. https:\/\/doi.org\/10.1097\/00002030-199912030-00012","journal-title":"AIDS"},{"issue":"7408","key":"4421_CR42","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nature11286","volume":"487","author":"NM Archin","year":"2012","unstructured":"Archin NM et al (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487(7408):482\u2013485. https:\/\/doi.org\/10.1038\/nature11286","journal-title":"Nature"},{"key":"4421_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000026","author":"NM Archin","year":"2014","unstructured":"Archin NM, Margolis DM (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis. https:\/\/doi.org\/10.1097\/QCO.0000000000000026","journal-title":"Curr Opin Infect Dis"},{"key":"4421_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00895","author":"M Aid","year":"2018","unstructured":"Aid M et al (2018) Follicular CD4 T helper cells as a major HIV reservoir compartment: a molecular perspective. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.00895","journal-title":"Front Immunol"},{"key":"4421_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw189","author":"HM Delagr\u00e8verie","year":"2016","unstructured":"Delagr\u00e8verie HM, Delaugerre C, Lewin SR, Deeks SG, Li JZ (2016) Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofw189 (Oxford University Press)","journal-title":"Open Forum Infect Dis"},{"key":"4421_CR46","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3390\/PH3092751","volume":"3","author":"S Subramanian","year":"2010","unstructured":"Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 2010 3:2751\u20132767. https:\/\/doi.org\/10.3390\/PH3092751","journal-title":"Pharmaceuticals 2010"},{"issue":"7","key":"4421_CR47","first-page":"2142","volume":"8","author":"A Patnaik","year":"2002","unstructured":"Patnaik A et al (2002) A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res 8(7):2142\u20132148","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4421_CR48","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/S10637-006-9017-4","volume":"25","author":"LH Camacho","year":"2007","unstructured":"Camacho LH, Olson J, Tong WP, Young CW, Spriggs DR, Malkin MG (2007) Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs 25(2):131\u2013138. https:\/\/doi.org\/10.1007\/S10637-006-9017-4","journal-title":"Invest New Drugs"},{"issue":"2","key":"4421_CR49","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/SJ.BJC.6603851","volume":"97","author":"A Atmaca","year":"2007","unstructured":"Atmaca A et al (2007) Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial. Br J Cancer 97(2):177\u2013182. https:\/\/doi.org\/10.1038\/SJ.BJC.6603851","journal-title":"Br J Cancer"},{"issue":"3","key":"4421_CR50","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1600-0609.2008.01102.x","volume":"81","author":"P Gimsing","year":"2008","unstructured":"Gimsing P et al (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol 81(3):170\u2013176. https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01102.x","journal-title":"Eur J Haematol"},{"issue":"18 Pt 1","key":"4421_CR51","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1158\/1078-0432.CCR-07-0791","volume":"13","author":"S Kummar","year":"2007","unstructured":"Kummar S et al (2007) Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res 13(18 Pt 1):5411\u20135417. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0791","journal-title":"Clin Cancer Res"},{"issue":"21","key":"4421_CR52","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA et al (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25(21):3109\u20133115. https:\/\/doi.org\/10.1200\/JCO.2006.10.2434","journal-title":"J Clin Oncol"},{"issue":"5","key":"4421_CR53","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1093\/ANNONC\/MDN031","volume":"19","author":"M Crump","year":"2008","unstructured":"Crump M et al (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19(5):964\u2013969. https:\/\/doi.org\/10.1093\/ANNONC\/MDN031","journal-title":"Ann Oncol"},{"issue":"12","key":"4421_CR54","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","volume":"27","author":"E Galanis","year":"2009","unstructured":"Galanis E et al (2009) Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 27(12):2052\u20132058. https:\/\/doi.org\/10.1200\/JCO.2008.19.0694","journal-title":"J Clin Oncol"},{"issue":"9485","key":"4421_CR55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0140-6736(05)67098-5","volume":"366","author":"G Lehrman","year":"2005","unstructured":"Lehrman G et al (2005) Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366(9485):549\u2013555. https:\/\/doi.org\/10.1016\/S0140-6736(05)67098-5","journal-title":"Lancet"},{"issue":"1","key":"4421_CR56","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/COH.0b013e328341242d","volume":"6","author":"DM Margolis","year":"2011","unstructured":"Margolis DM (2011) Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS 6(1):25\u201329. https:\/\/doi.org\/10.1097\/COH.0b013e328341242d","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"4421_CR57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.3152","volume":"16","author":"TW Chun","year":"2015","unstructured":"Chun TW, Moir S, Fauci AS (2015) HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol 16(6):584\u2013589. https:\/\/doi.org\/10.1038\/ni.3152","journal-title":"Nat Immunol"},{"issue":"1","key":"4421_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/NSMB.3328","volume":"24","author":"HC Chen","year":"2017","unstructured":"Chen HC, Martinez JP, Zorita E, Meyerhans A, Filion GJ (2017) Position effects influence HIV latency reversal. Nat Struct Mol Biol 24(1):47\u201354. https:\/\/doi.org\/10.1038\/NSMB.3328","journal-title":"Nat Struct Mol Biol"},{"key":"4421_CR59","doi-asserted-by":"publisher","DOI":"10.7554\/ELIFE.34655","author":"E Battivelli","year":"2018","unstructured":"Battivelli E et al (2018) Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells. Elife. https:\/\/doi.org\/10.7554\/ELIFE.34655","journal-title":"Elife"},{"issue":"12","key":"4421_CR60","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/QAD.0B013E32835535F5","volume":"26","author":"S Bouchat","year":"2012","unstructured":"Bouchat S et al (2012) Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26(12):1473\u20131482. https:\/\/doi.org\/10.1097\/QAD.0B013E32835535F5","journal-title":"AIDS"},{"key":"4421_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0006093","author":"S Reuse","year":"2009","unstructured":"Reuse S et al (2009) Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0006093","journal-title":"PLoS ONE"},{"issue":"16","key":"4421_CR62","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.1128\/JVI.00572-15","volume":"89","author":"MK Tripathy","year":"2015","unstructured":"Tripathy MK, McManamy MEM, Burch BD, Archin NM, Margolis DM (2015) H3K27 demethylation at the proviral promoter sensitizes latent HIV to the effects of vorinostat in ex vivo cultures of resting CD4+ T cells. J Virol 89(16):8392\u20138405. https:\/\/doi.org\/10.1128\/JVI.00572-15","journal-title":"J Virol"},{"key":"4421_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PPAT.1005677","author":"M Abdel-Mohsen","year":"2016","unstructured":"Abdel-Mohsen M et al (2016) Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation. PLoS Pathog. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1005677","journal-title":"PLoS Pathog"},{"key":"4421_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02084-16","author":"MA Rochat","year":"2017","unstructured":"Rochat MA, Schlaepfer E, Speck RF (2017) Promising role of toll-like receptor 8 agonist in concert with prostratin for activation of silent HIV. J Virol. https:\/\/doi.org\/10.1128\/JVI.02084-16","journal-title":"J Virol"},{"issue":"33","key":"4421_CR65","doi-asserted-by":"publisher","first-page":"E7795","DOI":"10.1073\/PNAS.1803468115","volume":"115","author":"B Das","year":"2018","unstructured":"Das B et al (2018) Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proc Natl Acad Sci USA 115(33):E7795\u2013E7804. https:\/\/doi.org\/10.1073\/PNAS.1803468115","journal-title":"Proc Natl Acad Sci USA"},{"key":"4421_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-07814-4","author":"BJ Albert","year":"2017","unstructured":"Albert BJ et al (2017) Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-017-07814-4","journal-title":"Sci Rep"},{"issue":"6","key":"4421_CR67","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2174\/157016210793499312","volume":"8","author":"M Perez","year":"2010","unstructured":"Perez M et al (2010) Bryostatin-1 synergizes with histone deacetylase inhibitors to reactivate HIV-1 from latency. Curr HIV Res 8(6):418\u2013429. https:\/\/doi.org\/10.2174\/157016210793499312","journal-title":"Curr HIV Res"},{"issue":"1","key":"4421_CR68","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","volume":"23","author":"Y Kim","year":"2018","unstructured":"Kim Y, Anderson JL, Lewin SR (2018) Getting the \u2018Kill\u2019 into \u2018Shock and Kill\u2019: strategies to eliminate latent HIV. Cell Host Microbe 23(1):14\u201326. https:\/\/doi.org\/10.1016\/j.chom.2017.12.004","journal-title":"Cell Host Microbe"},{"issue":"4","key":"4421_CR69","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.cell.2019.10.002","volume":"179","author":"E Herzig","year":"2019","unstructured":"Herzig E et al (2019) Attacking latent HIV with convertibleCAR-T cells, a highly adaptable killing platform. Cell 179(4):880-894.e10. https:\/\/doi.org\/10.1016\/j.cell.2019.10.002","journal-title":"Cell"},{"key":"4421_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PPAT.1004071","author":"D Wei","year":"2014","unstructured":"Wei D et al (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1004071","journal-title":"PLoS Pathog"},{"issue":"1","key":"4421_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-07814-4","volume":"7","author":"BJ Albert","year":"2017","unstructured":"Albert BJ et al (2017) Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep 7(1):1\u201312. https:\/\/doi.org\/10.1038\/s41598-017-07814-4","journal-title":"Sci Rep"},{"issue":"18","key":"4421_CR72","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1097\/QAD.0000000000000067","volume":"27","author":"F Wightman","year":"2013","unstructured":"Wightman F et al (2013) Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. AIDS 27(18):2853\u20132862. https:\/\/doi.org\/10.1097\/QAD.0000000000000067","journal-title":"AIDS"},{"issue":"11","key":"4421_CR73","doi-asserted-by":"publisher","first-page":"6782","DOI":"10.1074\/JBC.M807898200","volume":"284","author":"X Contreras","year":"2009","unstructured":"Contreras X et al (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284(11):6782. https:\/\/doi.org\/10.1074\/JBC.M807898200","journal-title":"J Biol Chem"},{"issue":"5\u20136","key":"4421_CR74","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2119\/molmed.2011.00076","volume":"17","author":"S Matalon","year":"2011","unstructured":"Matalon S, Rasmussen TA, Dinarello CA (2011) Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 17(5\u20136):466\u2013472. https:\/\/doi.org\/10.2119\/molmed.2011.00076","journal-title":"Mol Med"},{"issue":"4","key":"4421_CR75","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/NM.3489","volume":"20","author":"C Bullen","year":"2014","unstructured":"Bullen C, Laird G, Durand C, Siliciano J, Siliciano R (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20(4):425\u2013429. https:\/\/doi.org\/10.1038\/NM.3489","journal-title":"Nat Med"},{"key":"4421_CR76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.EBIOM.2015.11.047","volume":"3","author":"M Stoszko","year":"2015","unstructured":"Stoszko M et al (2015) Small Molecule Inhibitors of BAF; a promising family of compounds in HIV-1 latency reversal. EBioMedicine 3:108\u2013121. https:\/\/doi.org\/10.1016\/J.EBIOM.2015.11.047","journal-title":"EBioMedicine"},{"issue":"7","key":"4421_CR77","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1128\/JVI.05972-11","volume":"86","author":"E Gallastegui","year":"2012","unstructured":"Gallastegui E et al (2012) Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol 86(7):3795\u20133808. https:\/\/doi.org\/10.1128\/JVI.05972-11","journal-title":"J Virol"},{"key":"4421_CR78","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02056-17","author":"E Abner","year":"2018","unstructured":"Abner E et al (2018) A new quinoline BRD4 inhibitor targets a distinct latent HIV-1 reservoir for reactivation from other \u2018Shock\u2019 drugs. J Virol. https:\/\/doi.org\/10.1128\/JVI.02056-17","journal-title":"J Virol."},{"issue":"6","key":"4421_CR79","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1189\/JLB.0312165","volume":"92","author":"C Banerjee","year":"2012","unstructured":"Banerjee C et al (2012) BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol 92(6):1147\u20131154. https:\/\/doi.org\/10.1189\/JLB.0312165","journal-title":"J Leukoc Biol"},{"issue":"4","key":"4421_CR80","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/J.CELREP.2012.09.008","volume":"2","author":"J Zhu","year":"2012","unstructured":"Zhu J et al (2012) Reactivation of latent HIV-1 by inhibition of BRD4. Cell Rep 2(4):807\u2013816. https:\/\/doi.org\/10.1016\/J.CELREP.2012.09.008","journal-title":"Cell Rep"},{"key":"4421_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000495","author":"SE Kauder","year":"2009","unstructured":"Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E (2009) Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1000495","journal-title":"PLoS Pathog"},{"key":"4421_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000554","author":"J Blazkova","year":"2009","unstructured":"Blazkova J et al (2009) CpG methylation controls reactivation of HIV from latency. PLoS Pathog. https:\/\/doi.org\/10.1371\/journal.ppat.1000554","journal-title":"PLoS Pathog"},{"issue":"24","key":"4421_CR83","doi-asserted-by":"publisher","first-page":"21083","DOI":"10.1074\/JBC.M110.195537","volume":"286","author":"S Micheva-Viteva","year":"2011","unstructured":"Micheva-Viteva S et al (2011) High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem 286(24):21083\u201321091. https:\/\/doi.org\/10.1074\/JBC.M110.195537","journal-title":"J Biol Chem"},{"issue":"5","key":"4421_CR84","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/J.CELREP.2017.01.022","volume":"18","author":"A Bosque","year":"2017","unstructured":"Bosque A et al (2017) Benzotriazoles reactivate latent HIV-1 through inactivation of STAT5 SUMOylation. Cell Rep 18(5):1324\u20131334. https:\/\/doi.org\/10.1016\/J.CELREP.2017.01.022","journal-title":"Cell Rep"},{"issue":"4","key":"4421_CR85","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1099\/JGV.0.000716","volume":"98","author":"Y Kobayashi","year":"2017","unstructured":"Kobayashi Y, G\u00e9linas C, Dougherty J (2017) Histone deacetylase inhibitors containing a benzamide functional group and a pyridyl cap are preferentially effective human immunodeficiency virus-1 latency-reversing agents in primary resting CD4+ T cells. J Gen Virol 98(4):799\u2013809. https:\/\/doi.org\/10.1099\/JGV.0.000716","journal-title":"J Gen Virol"},{"key":"4421_CR86","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.virol.2018.05.006","volume":"520","author":"MD Marsden","year":"2018","unstructured":"Marsden MD et al (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83\u201393. https:\/\/doi.org\/10.1016\/j.virol.2018.05.006","journal-title":"Virology"},{"issue":"1","key":"4421_CR87","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0042-6822(92)90295-Z","volume":"187","author":"J Vlach","year":"1992","unstructured":"Vlach J, Pitha P (1992) Activation of human immunodeficiency virus type 1 provirus in T-cells and macrophages is associated with induction of inducer-specific NF-\u03baB binding proteins. Virology 187(1):63\u201372. https:\/\/doi.org\/10.1016\/0042-6822(92)90295-Z","journal-title":"Virology"},{"issue":"4","key":"4421_CR88","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.140.4.1117","volume":"140","author":"TM Folks","year":"1988","unstructured":"Folks TM et al (1988) Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol 140(4):1117\u20131122","journal-title":"J Immunol"},{"issue":"10","key":"4421_CR89","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1182\/BLOOD.V98.10.3006","volume":"98","author":"J Kulkosky","year":"2001","unstructured":"Kulkosky J et al (2001) Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 98(10):3006\u20133015. https:\/\/doi.org\/10.1182\/BLOOD.V98.10.3006","journal-title":"Blood"},{"issue":"11","key":"4421_CR90","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1097\/QAD.0000000000000289","volume":"28","author":"G Jiang","year":"2014","unstructured":"Jiang G et al (2014) Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C\u03b4-NF-\u03baB signaling. AIDS 28(11):1555\u20131566. https:\/\/doi.org\/10.1097\/QAD.0000000000000289","journal-title":"AIDS"},{"issue":"1","key":"4421_CR91","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/J.VIROL.2014.05.033","volume":"462\u2013463","author":"D Pandel\u00f3 Jos\u00e9","year":"2014","unstructured":"Pandel\u00f3 Jos\u00e9 D et al (2014) Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 462\u2013463(1):328\u2013339. https:\/\/doi.org\/10.1016\/J.VIROL.2014.05.033","journal-title":"Virology"},{"key":"4421_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/S12977-017-0335-8","author":"D Alvarez-Carbonell","year":"2017","unstructured":"Alvarez-Carbonell D et al (2017) Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells. Retrovirology. https:\/\/doi.org\/10.1186\/S12977-017-0335-8","journal-title":"Retrovirology"},{"key":"4421_CR93","doi-asserted-by":"publisher","DOI":"10.1172\/JCI.INSIGHT.122673","author":"A Macedo","year":"2018","unstructured":"Macedo A et al (2018) Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.122673","journal-title":"JCI Insight"},{"issue":"1\u20132","key":"4421_CR94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/J.VIROL.2009.04.019","volume":"389","author":"S Thibault","year":"2009","unstructured":"Thibault S, Imbeault M, Tardif MR, Tremblay MJ (2009) TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells. Virology 389(1\u20132):20\u201325. https:\/\/doi.org\/10.1016\/J.VIROL.2009.04.019","journal-title":"Virology"},{"issue":"5","key":"4421_CR95","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/JIMMUNOL.176.5.2888","volume":"176","author":"E Schlaepfer","year":"2006","unstructured":"Schlaepfer E, Audig\u00e9 A, Joller H, Speck RF (2006) TLR7\/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 176(5):2888\u20132895. https:\/\/doi.org\/10.4049\/JIMMUNOL.176.5.2888","journal-title":"J Immunol"},{"key":"4421_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0062074","author":"AA Winckelmann","year":"2013","unstructured":"Winckelmann AA et al (2013) Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0062074","journal-title":"PLoS ONE"},{"key":"4421_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-02634-Y","author":"M L\u00f3pez-Huertas","year":"2017","unstructured":"L\u00f3pez-Huertas M et al (2017) The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-017-02634-Y","journal-title":"Sci Rep"},{"key":"4421_CR98","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01931-17","author":"N Madrid-Elena","year":"2018","unstructured":"Madrid-Elena N et al (2018) Maraviroc is associated with latent HIV-1 reactivation through NF-\u03baB activation in resting CD4 + T cells from HIV-infected individuals on suppressive antiretroviral therapy. J Virol. https:\/\/doi.org\/10.1128\/JVI.01931-17","journal-title":"J Virol"},{"issue":"2","key":"4421_CR99","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.142.2.702","volume":"142","author":"SE Tong-Starksen","year":"1989","unstructured":"Tong-Starksen SE, Luciw PA, Peterlin BM (1989) Signaling through T lymphocyte surface proteins, TCR\/CD3 and CD28, activates the HIV-1 long terminal repeat. J Immunol 142(2):702\u2013707","journal-title":"J Immunol"},{"issue":"12","key":"4421_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/JOURNAL.PPAT.1003834","volume":"9","author":"CA Spina","year":"2013","unstructured":"Spina CA et al (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9(12):1\u201315. https:\/\/doi.org\/10.1371\/JOURNAL.PPAT.1003834","journal-title":"PLoS Pathog"},{"issue":"1\u20132","key":"4421_CR101","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/J.VIROL.2013.07.037","volume":"446","author":"V Calvanese","year":"2013","unstructured":"Calvanese V, Chavez L, Laurent T, Ding S, Verdin E (2013) Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology 446(1\u20132):283\u2013292. https:\/\/doi.org\/10.1016\/J.VIROL.2013.07.037","journal-title":"Virology"},{"issue":"4833","key":"4421_CR102","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1126\/SCIENCE.2825351","volume":"238","author":"M Siekevitz","year":"1987","unstructured":"Siekevitz M, Josephs SF, Dukovich M, Peffer N, Wong-Staal F, Greene WC (1987) Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science 238(4833):1575\u20131578. https:\/\/doi.org\/10.1126\/SCIENCE.2825351","journal-title":"Science"},{"key":"4421_CR103","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0084964","author":"G Doyon","year":"2014","unstructured":"Doyon G, Sobolewski MD, Huber K, McMahon D, Mellors JW, Sluis-Cremer N (2014) Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110\u03b1 that reactivates latent HIV-1. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0084964","journal-title":"PLoS ONE"},{"key":"4421_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.VIRUSRES.2016.09.015","volume":"227","author":"H Lim","year":"2017","unstructured":"Lim H et al (2017) Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor. Virus Res 227:1\u20135. https:\/\/doi.org\/10.1016\/J.VIRUSRES.2016.09.015","journal-title":"Virus Res"},{"issue":"2","key":"4421_CR105","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/JAC\/DKR496","volume":"67","author":"S Xing","year":"2012","unstructured":"Xing S et al (2012) Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 67(2):398\u2013403. https:\/\/doi.org\/10.1093\/JAC\/DKR496","journal-title":"J Antimicrob Chemother"},{"key":"4421_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/MOLECULES22101703","author":"P Kapewangolo","year":"2017","unstructured":"Kapewangolo P, Omolo JJ, Fonteh P, Kandawa-Schulz M, Meyer D (2017) Triterpenoids from Ocimum labiatum activates latent HIV-1 expression in vitro: potential for use in adjuvant therapy. Molecules. https:\/\/doi.org\/10.3390\/MOLECULES22101703","journal-title":"Molecules"},{"key":"4421_CR107","unstructured":"Research Toward a Cure Trials \u2013 Treatment Action Group. https:\/\/www.treatmentactiongroup.org\/cure\/trials\/ (accessed May 23, 2022)"},{"key":"4421_CR108","unstructured":"Two-year virologic outcomes of very early art for infants in the impact P1115 STUDY. https:\/\/www.croiconference.org\/abstract\/two-year-virologic-outcomes-of-very-early-art-for-infants-in-the-impaact-p1115-study\/ (accessed May 23, 2022)."},{"key":"4421_CR109","unstructured":"Treatment with broadly neutralizing antibodies in children with HIV in Botswana. https:\/\/www.croiconference.org\/abstract\/treatment-with-broadly-neutralizing-antibodies-in-children-with-hiv-in-botswana\/ (accessed May 23, 2022)."},{"key":"4421_CR110","unstructured":"Safety and pharmacokinetics of vrc01ls and 10\u20131074 among children in Botswana. https:\/\/www.croiconference.org\/abstract\/safety-and-pharmacokinetics-of-vrc01ls-and-10-1074-among-children-in-botswana\/ (accessed May 23, 2022)."},{"key":"4421_CR111","doi-asserted-by":"publisher","unstructured":"Rom\u00e1n VRG et al (2013) Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in guinea-bissau. AIDS Res Hum Retroviruses 29(11):1504\u20131512. https:\/\/home.liebertpub.com\/aid, https:\/\/doi.org\/10.1089\/AID.2013.0076","DOI":"10.1089\/AID.2013.0076"},{"issue":"34","key":"4421_CR112","doi-asserted-by":"publisher","first-page":"23353","DOI":"10.1074\/jbc.M709651200","volume":"283","author":"K Suzuki","year":"2008","unstructured":"Suzuki K et al (2008) Closed chromatin architecture is induced by an RNA duplex targeting the HIV-1 promoter region. J Biol Chem 283(34):23353\u201323363. https:\/\/doi.org\/10.1074\/jbc.M709651200","journal-title":"J Biol Chem"},{"issue":"10","key":"4421_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.31","volume":"4","author":"C Ahlenstiel","year":"2015","unstructured":"Ahlenstiel C et al (2015) Novel RNA duplex locks HIV-1 in a latent state via chromatin-mediated transcriptional silencing. Mol Ther- Nucleic Acids 4(10):e261. https:\/\/doi.org\/10.1038\/mtna.2015.31","journal-title":"Mol Ther- Nucleic Acids"},{"issue":"6309","key":"4421_CR114","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.aaf8094","volume":"354","author":"RC Gallo","year":"2016","unstructured":"Gallo RC (2016) Shock and kill with caution. Science (1979) 354(6309):177\u2013178. https:\/\/doi.org\/10.1126\/science.aaf8094","journal-title":"Science (1979)"},{"issue":"2","key":"4421_CR115","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1586\/14787210.2016.1122525","volume":"14","author":"G Mousseau","year":"2016","unstructured":"Mousseau G, Valente ST (2016) Didehydro-Cortistatin A: a new player in HIV-therapy? Expert Rev Anti Infect Ther 14(2):145\u2013148. https:\/\/doi.org\/10.1586\/14787210.2016.1122525","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"4421_CR116","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.chom.2012.05.016","volume":"12","author":"G Mousseau","year":"2012","unstructured":"Mousseau G et al (2012) An analog of the natural steroidal alkaloid cortistatin A potently suppresses tat-dependent HIV transcription. Cell Host Microbe 12(1):97\u2013108. https:\/\/doi.org\/10.1016\/j.chom.2012.05.016","journal-title":"Cell Host Microbe"},{"issue":"1","key":"4421_CR117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/MBIO.02662-18","volume":"10","author":"S Mediouni","year":"2019","unstructured":"Mediouni S et al (2019) Didehydro-cortistatin a inhibits HIV-1 by specifically binding to the unstructured basic region of tat. MBio 10(1):1\u201319. https:\/\/doi.org\/10.1128\/MBIO.02662-18","journal-title":"MBio"},{"key":"4421_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/v12121443","author":"I Moranguinho","year":"2020","unstructured":"Moranguinho I, Valente ST (2020) Block-and-lock: new horizons for a cure for HIV-1. Viruses. https:\/\/doi.org\/10.3390\/v12121443 (NLM (Medline))","journal-title":"Viruses"},{"issue":"1","key":"4421_CR119","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/infdis\/jiaa681","volume":"223","author":"C Li","year":"2021","unstructured":"Li C, Mori L, Valente ST (2021) The block-and-lock strategy for human immunodeficiency virus cure: lessons learned from didehydro-cortistatin A. J Infect Dis 223(1):46\u201353. https:\/\/doi.org\/10.1093\/infdis\/jiaa681","journal-title":"J Infect Dis"},{"key":"4421_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/v12050529","author":"L Mori","year":"2020","unstructured":"Mori L, Valente ST (2020) Key players in HIV-1 transcriptional regulation: targets for a functional cure. Viruses. https:\/\/doi.org\/10.3390\/v12050529 (MDPI AG)","journal-title":"Viruses"},{"issue":"3","key":"4421_CR121","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/J.CELREP.2017.09.080","volume":"21","author":"CF Kessing","year":"2017","unstructured":"Kessing CF et al (2017) In vivo suppression of HIV rebound by didehydro-cortistatin A, a \u2018block-and-lock\u2019 strategy for HIV-1 treatment. Cell Rep 21(3):600\u2013611. https:\/\/doi.org\/10.1016\/J.CELREP.2017.09.080","journal-title":"Cell Rep"},{"issue":"7","key":"4421_CR122","doi-asserted-by":"publisher","first-page":"8280","DOI":"10.1096\/fj.201801165R","volume":"33","author":"S Mediouni","year":"2019","unstructured":"Mediouni S et al (2019) The Tat inhibitor didehydro-cortistatin A suppresses SIV replication and reactivation. FASEB J 33(7):8280\u20138293. https:\/\/doi.org\/10.1096\/fj.201801165R","journal-title":"FASEB J"},{"issue":"1","key":"4421_CR123","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1570162x13666150121111548","volume":"13","author":"S Mediouni","year":"2015","unstructured":"Mediouni S et al (2015) Didehydro-cortistatin A inhibits HIV-1 tat mediated neuroinflammation and prevents potentiation of cocaine reward in tat transgenic mice. Curr HIV Res 13(1):64\u201379. https:\/\/doi.org\/10.2174\/1570162x13666150121111548","journal-title":"Curr HIV Res"},{"key":"4421_CR124","doi-asserted-by":"publisher","DOI":"10.1128\/MBIO.01750-18","author":"G Mousseau","year":"2019","unstructured":"Mousseau G et al (2019) Resistance to the tat inhibitor didehydro-cortistatin A is mediated by heightened basal HIV-1 transcription. MBio. https:\/\/doi.org\/10.1128\/MBIO.01750-18","journal-title":"MBio"},{"key":"4421_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-014-0088-6","author":"Z Wan","year":"2014","unstructured":"Wan Z, Chen X (2014) Triptolide inhibits human immunodeficiency virus type 1 replication by promoting proteasomal degradation of Tat protein. Retrovirology. https:\/\/doi.org\/10.1186\/s12977-014-0088-6","journal-title":"Retrovirology"},{"issue":"3","key":"4421_CR126","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nchembio.522","volume":"7","author":"DV Titov","year":"2011","unstructured":"Titov DV et al (2011) XPB, a subunit of TFIIH, is a target of the natural product triptolide. Nat Chem Biol 7(3):182\u2013188. https:\/\/doi.org\/10.1038\/nchembio.522","journal-title":"Nat Chem Biol"},{"key":"4421_CR127","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.antiviral.2017.08.013","volume":"146","author":"T Hayashi","year":"2017","unstructured":"Hayashi T, Jean M, Huang H, Simpson S, Santoso NG, Zhu J (2017) Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription. Antiviral Res 146:76\u201385. https:\/\/doi.org\/10.1016\/j.antiviral.2017.08.013","journal-title":"Antiviral Res"},{"key":"4421_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/v12010084","author":"G Vansant","year":"2020","unstructured":"Vansant G, Bruggemans A, Janssens J, Debyser Z (2020) Block-and-lock strategies to cure HIV infection. Viruses. https:\/\/doi.org\/10.3390\/v12010084 (MDPI AG)","journal-title":"Viruses"},{"issue":"3","key":"4421_CR129","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/COH.0b013e32835f736c","volume":"8","author":"D Stone","year":"2013","unstructured":"Stone D, Kiem HP, Jerome KR (2013) Targeted gene disruption to cure HIV. Curr Opin HIV AIDS 8(3):217\u2013223. https:\/\/doi.org\/10.1097\/COH.0b013e32835f736c (NIH Public Access)","journal-title":"Curr Opin HIV AIDS"},{"key":"4421_CR130","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169931","author":"M Zaboikin","year":"2017","unstructured":"Zaboikin M, Zaboikina T, Freter C, Srinivasakumar N (2017) Non-homologous end joining and homology directed DNA repair frequency of double-stranded breaks introduced by genome editing reagents. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0169931","journal-title":"PLoS ONE"},{"issue":"21","key":"4421_CR131","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1182\/blood-2016-01-678144","volume":"127","author":"CX Wang","year":"2016","unstructured":"Wang CX, Cannon PM (2016) The clinical applications of genome editing in HIV. Blood 127(21):2546\u20132552. https:\/\/doi.org\/10.1182\/blood-2016-01-678144 (American Society of Hematology)","journal-title":"Blood"},{"issue":"5","key":"4421_CR132","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nrd4316","volume":"13","author":"B Owens","year":"2014","unstructured":"Owens B (2014) Zinc-finger nucleases make the cut in HIV. Nat Rev Drug Discovery 13(5):321\u2013322. https:\/\/doi.org\/10.1038\/nrd4316","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"4421_CR133","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1534\/genetics.111.131433","volume":"188","author":"D Carroll","year":"2011","unstructured":"Carroll D (2011) Genome engineering with zinc-finger nucleases. Genetics 188(4):773\u2013782. https:\/\/doi.org\/10.1534\/genetics.111.131433","journal-title":"Genetics"},{"key":"4421_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-017-0157-8","author":"A Kwarteng","year":"2017","unstructured":"Kwarteng A, Ahuno ST, Kwakye-Nuako G (2017) The therapeutic landscape of HIV-1 via genome editing. AIDS Res Ther. https:\/\/doi.org\/10.1186\/s12981-017-0157-8 (BioMed Central Ltd.)","journal-title":"AIDS Res Ther"},{"issue":"4","key":"4421_CR135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002020","volume":"7","author":"CB Wilen","year":"2011","unstructured":"Wilen CB et al (2011) Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 7(4):e1002020. https:\/\/doi.org\/10.1371\/journal.ppat.1002020","journal-title":"PLoS Pathog"},{"issue":"4","key":"4421_CR136","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/mt.2011.310","volume":"20","author":"J Yuan","year":"2012","unstructured":"Yuan J et al (2012) Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4 T cell resistance and enrichment. Mol Ther 20(4):849\u2013859. https:\/\/doi.org\/10.1038\/mt.2011.310","journal-title":"Mol Ther"},{"issue":"7","key":"4421_CR137","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nbt1410","volume":"26","author":"EE Perez","year":"2008","unstructured":"Perez EE et al (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26(7):808\u2013816. https:\/\/doi.org\/10.1038\/nbt1410","journal-title":"Nat Biotechnol"},{"issue":"8","key":"4421_CR138","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.1663","volume":"28","author":"N Holt","year":"2010","unstructured":"Holt N et al (2010) Human hematopoietic stem\/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28(8):839\u2013847. https:\/\/doi.org\/10.1038\/nbt.1663","journal-title":"Nat Biotechnol"},{"issue":"6","key":"4421_CR139","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/mt.2013.65","volume":"21","author":"L Li","year":"2013","unstructured":"Li L et al (2013) Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 21(6):1259\u20131269. https:\/\/doi.org\/10.1038\/mt.2013.65","journal-title":"Mol Ther"},{"issue":"7","key":"4421_CR140","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1101\/gr.122879.111","volume":"22","author":"J Wang","year":"2012","unstructured":"Wang J et al (2012) Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res 22(7):1316\u20131326. https:\/\/doi.org\/10.1101\/gr.122879.111","journal-title":"Genome Res"},{"issue":"7","key":"4421_CR141","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dku072","volume":"69","author":"R Badia","year":"2014","unstructured":"Badia R, Riveira-Mu\u00f1oz E, Clotet B, Est\u00e9 JA, Ballana E (2014) Gene editing using a zinc-finger nuclease mimicking the CCR5\u039432 mutation induces resistance to CCR5-using HIV-1. J Antimicrob Chemother 69(7):1755\u20131759. https:\/\/doi.org\/10.1093\/jac\/dku072","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4421_CR142","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1089\/hum.2011.126","volume":"23","author":"Y Yao","year":"2012","unstructured":"Yao Y et al (2012) Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells. Hum Gene Ther 23(2):238\u2013242. https:\/\/doi.org\/10.1089\/hum.2011.126","journal-title":"Hum Gene Ther"},{"issue":"10","key":"4421_CR143","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/nejmoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P et al (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370(10):901\u2013910. https:\/\/doi.org\/10.1056\/nejmoa1300662","journal-title":"N Engl J Med"},{"issue":"5959","key":"4421_CR144","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.1178817","volume":"326","author":"MJ Moscou","year":"2009","unstructured":"Moscou MJ, Bogdanove AJ (2009) A simple cipher governs DNA recognition by TAL effectors. Science (1979) 326(5959):1501. https:\/\/doi.org\/10.1126\/science.1178817","journal-title":"Science (1979)"},{"issue":"5959","key":"4421_CR145","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1126\/science.1178811","volume":"326","author":"J Boch","year":"2009","unstructured":"Boch J et al (2009) Breaking the code of DNA binding specificity of TAL-type III effectors. Science (1979) 326(5959):1509\u20131512. https:\/\/doi.org\/10.1126\/science.1178811","journal-title":"Science (1979)"},{"issue":"4","key":"4421_CR146","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.pbi.2010.04.010","volume":"13","author":"AJ Bogdanove","year":"2010","unstructured":"Bogdanove AJ, Schornack S, Lahaye T (2010) TAL effectors: finding plant genes for disease and defense. Curr Opin Plant Biol 13(4):394\u2013401. https:\/\/doi.org\/10.1016\/j.pbi.2010.04.010","journal-title":"Curr Opin Plant Biol"},{"issue":"2","key":"4421_CR147","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/QAI.0000000000001190","volume":"74","author":"B Shi","year":"2017","unstructured":"Shi B et al (2017) TALEN-mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus. J Acquir Immune Defic Syndr 74(2):229\u2013241. https:\/\/doi.org\/10.1097\/QAI.0000000000001190","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"4421_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125652","volume":"10","author":"CL Strong","year":"2015","unstructured":"Strong CL, Guerra HP, Mathew KR, Roy N, Simpson LR, Schiller MR (2015) Damaging the integrated HIV proviral DNA with TALENs. PLoS ONE 10(5):e0125652. https:\/\/doi.org\/10.1371\/journal.pone.0125652","journal-title":"PLoS ONE"},{"key":"4421_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.01001","author":"T Kishida","year":"2016","unstructured":"Kishida T, Ejima A, Mazda O (2016) Specific destruction of HIV proviral p17 gene in T lymphoid cells achieved by the genome editing technology. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2016.01001","journal-title":"Front Microbiol"},{"issue":"1","key":"4421_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep06409","volume":"4","author":"U Mock","year":"2014","unstructured":"Mock U et al (2014) Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases. Sci Rep 4(1):1\u20138. https:\/\/doi.org\/10.1038\/srep06409","journal-title":"Sci Rep"},{"issue":"4","key":"4421_CR151","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.molcel.2015.02.032","volume":"58","author":"SH Sternberg","year":"2015","unstructured":"Sternberg SH, Doudna JA (2015) Expanding the biologist\u2019s toolkit with CRISPR-Cas9. Mol Cell 58(4):568\u2013574. https:\/\/doi.org\/10.1016\/j.molcel.2015.02.032 (Cell Press)","journal-title":"Mol Cell"},{"key":"4421_CR152","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA et al (2020) CRISPR-engineered T cells in patients with refractory cancer. Science (1979). https:\/\/doi.org\/10.1126\/science.aba7365","journal-title":"Science (1979)"},{"key":"4421_CR153","doi-asserted-by":"crossref","unstructured":"Frangoul H (2020) Safety and efficacy of CTX001 in patients with transfusion-dependent \u03b2-thalassemia and sickle cell disease: early results from the climb THAL-111 and climb SCD-121 studies of autologous CRISPR-CAS9\u2013modified CD34+ hematopoietic stem and progenitor cells. ASH","DOI":"10.1182\/blood-2020-139575"},{"issue":"4","key":"4421_CR154","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.stem.2020.01.019","volume":"26","author":"MH Geurts","year":"2020","unstructured":"Geurts MH et al (2020) CRISPR-based adenine editors correct nonsense mutations in a cystic fibrosis organoid biobank. Cell Stem Cell 26(4):503\u2013510. https:\/\/doi.org\/10.1016\/j.stem.2020.01.019 (e7)","journal-title":"Cell Stem Cell"},{"issue":"1","key":"4421_CR155","doi-asserted-by":"publisher","first-page":"eaap9004","DOI":"10.1126\/sciadv.aap9004","volume":"4","author":"C Long","year":"2018","unstructured":"Long C et al (2018) Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv 4(1):eaap9004. https:\/\/doi.org\/10.1126\/sciadv.aap9004","journal-title":"Sci Adv"},{"issue":"1","key":"4421_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep02510","volume":"3","author":"H Ebina","year":"2013","unstructured":"Ebina H, Misawa N, Kanemura Y, Koyanagi Y (2013) Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep 3(1):1\u20137. https:\/\/doi.org\/10.1038\/srep02510","journal-title":"Sci Rep"},{"key":"4421_CR157","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115987","author":"W Wang","year":"2014","unstructured":"Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P (2014) CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0115987","journal-title":"PLoS ONE"},{"issue":"26","key":"4421_CR158","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1073\/pnas.1407473111","volume":"111","author":"L Ye","year":"2014","unstructured":"Ye L et al (2014) Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5\u039432 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111(26):9591\u20139596. https:\/\/doi.org\/10.1073\/pnas.1407473111","journal-title":"Proc Natl Acad Sci USA"},{"key":"4421_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/srep15577","author":"P Hou","year":"2015","unstructured":"Hou P et al (2015) Genome editing of CXCR4 by CRISPR\/cas9 confers cells resistant to HIV-1 infection. Sci Rep. https:\/\/doi.org\/10.1038\/srep15577","journal-title":"Sci Rep"},{"issue":"12","key":"4421_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.42","volume":"4","author":"HJ Kang","year":"2015","unstructured":"Kang HJ, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II (2015) CCR5 disruption in induced pluripotent stem cells using CRISPR\/Cas9 provides selective resistance of immune cells to CCR5-tropic HIV-1 virus. Mol Ther-Nucleic Acids 4(12):e268. https:\/\/doi.org\/10.1038\/mtna.2015.42","journal-title":"Mol Ther-Nucleic Acids"},{"key":"4421_CR161","doi-asserted-by":"publisher","DOI":"10.3390\/v10010040","author":"S Chen","year":"2018","unstructured":"Chen S, Yu X, Guo D (2018) CRISPR-Cas targeting of host genes as an antiviral strategy. Viruses. https:\/\/doi.org\/10.3390\/v10010040","journal-title":"Viruses"},{"key":"4421_CR162","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.omtn.2018.05.012","volume":"12","author":"C Qi","year":"2018","unstructured":"Qi C et al (2018) Inducing CCR5\u039432\/\u039432 homozygotes in the human jurkat CD4+ cell line and primary CD4+ cells by CRISPR-Cas9 genome-editing technology. Mol Ther- Nucleic Acids 12:267\u2013274. https:\/\/doi.org\/10.1016\/j.omtn.2018.05.012","journal-title":"Mol Ther- Nucleic Acids"},{"issue":"3","key":"4421_CR163","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.2507","volume":"31","author":"SW Cho","year":"2013","unstructured":"Cho SW, Kim S, Kim JM, Kim JS (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31(3):230\u2013232. https:\/\/doi.org\/10.1038\/nbt.2507","journal-title":"Nat Biotechnol"},{"key":"4421_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/srep16277","author":"Y Zhang","year":"2015","unstructured":"Zhang Y et al (2015) CRISPR\/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep. https:\/\/doi.org\/10.1038\/srep16277","journal-title":"Sci Rep"},{"key":"4421_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158294","author":"JK Bialek","year":"2016","unstructured":"Bialek JK et al (2016) Targeted HIV-1 latency reversal using CRISPR\/Cas9-derived transcriptional activator systems. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0158294","journal-title":"PLoS ONE"},{"key":"4421_CR166","doi-asserted-by":"publisher","DOI":"10.19185\/matters.201611000027","author":"V Kim","year":"2017","unstructured":"Kim V, Mears B, Powell B, Witwer K (2017) Mutant Cas9-transcriptional activator activates HIV-1 in U1 cells in the presence and absence of LTR-specific guide RNAs. Matters (Zur). https:\/\/doi.org\/10.19185\/matters.201611000027","journal-title":"Matters (Zur)"},{"issue":"3","key":"4421_CR167","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/mt.2015.213","volume":"24","author":"P Limsirichai","year":"2016","unstructured":"Limsirichai P, Gaj T, Schaffer DV (2016) CRISPR-mediated activation of latent HIV-1 expression. Mol Ther 24(3):499\u2013507. https:\/\/doi.org\/10.1038\/mt.2015.213","journal-title":"Mol Ther"},{"issue":"3","key":"4421_CR168","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.bbamcr.2018.09.012","volume":"1866","author":"M Chemudupati","year":"2019","unstructured":"Chemudupati M et al (2019) From APOBEC to ZAP: diverse mechanisms used by cellular restriction factors to inhibit virus infections. Biochem Biophys Acta 1866(3):382\u2013394. https:\/\/doi.org\/10.1016\/j.bbamcr.2018.09.012 (Elsevier B.V.)","journal-title":"Biochem Biophys Acta"},{"issue":"MAR","key":"4421_CR169","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2019.00069","volume":"9","author":"Q Xiao","year":"2019","unstructured":"Xiao Q, Guo D, Chen S (2019) Application of CRISPR\/Cas9-based gene editing in HIV-1\/AIDS therapy. Front Cell Infect Microbiol 9(MAR):1\u201315. https:\/\/doi.org\/10.3389\/fcimb.2019.00069","journal-title":"Front Cell Infect Microbiol"},{"issue":"52","key":"4421_CR170","doi-asserted-by":"publisher","first-page":"E7249","DOI":"10.1073\/pnas.1516305112","volume":"112","author":"HP Bogerd","year":"2015","unstructured":"Bogerd HP, Kornepati AVR, Marshall JB, Kennedy EM, Cullen BR (2015) Specific induction of endogenous viral restriction factors using CRISPR\/Cas-derived transcriptional activators. Proc Natl Acad Sci USA 112(52):E7249\u2013E7256. https:\/\/doi.org\/10.1073\/pnas.1516305112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4421_CR171","doi-asserted-by":"publisher","first-page":"9","DOI":"10.16288\/j.yczz.15-284","volume":"38","author":"Y Han","year":"2016","unstructured":"Han Y, Li Q (2016) Application progress of CRISPR\/Cas9 genome editing technology in the treatment of HIV-1 infection. Yi chuan = Hereditas \/ Zhongguo yi chuan xue hui bian ji 38(1):9\u201316. https:\/\/doi.org\/10.16288\/j.yczz.15-284 (Yi Chuan)","journal-title":"Yi chuan = Hereditas \/ Zhongguo yi chuan xue hui bian ji"},{"key":"4421_CR172","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jbiotec.2018.08.007","volume":"284","author":"ML Kimberland","year":"2018","unstructured":"Kimberland ML et al (2018) Strategies for controlling CRISPR\/Cas9 off-target effects and biological variations in mammalian genome editing experiments. J Biotechnol 284:91\u2013101. https:\/\/doi.org\/10.1016\/j.jbiotec.2018.08.007 (Elsevier B.V.)","journal-title":"J Biotechnol"},{"issue":"00","key":"4421_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bfgp\/elz021","volume":"00","author":"E Herrera-Carrillo","year":"2019","unstructured":"Herrera-Carrillo E, Gao Z, Berkhout B (2019) CRISPR therapy towards an HIV cure. Brief Funct Genomics 00(00):1\u20138. https:\/\/doi.org\/10.1093\/bfgp\/elz021","journal-title":"Brief Funct Genomics"},{"issue":"6","key":"4421_CR174","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"W Wold","year":"2014","unstructured":"Wold W, Toth K (2014) Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13(6):421\u2013433. https:\/\/doi.org\/10.2174\/1566523213666131125095046","journal-title":"Curr Gene Ther"},{"key":"4421_CR175","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/mtm.2016.30","volume":"3","author":"S Afkhami","year":"2016","unstructured":"Afkhami S, Yao Y, Xing Z (2016) Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther Methods Clin Dev 3:16030. https:\/\/doi.org\/10.1038\/mtm.2016.30 (Elsevier Inc)","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"13","key":"4421_CR176","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00018-017-2479-z","volume":"74","author":"K Khalili","year":"2017","unstructured":"Khalili K, White MK, Jacobson JM (2017) Novel AIDS therapies based on gene editing. Cell Mol Life Sci 74(13):2439\u20132450. https:\/\/doi.org\/10.1007\/s00018-017-2479-z (Birkhauser Verlag AG)","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4421_CR177","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3018(15)00232-5","volume":"3","author":"P Frange","year":"2016","unstructured":"Frange P et al (2016) HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. The Lancet HIV 3(1):e49\u2013e54. https:\/\/doi.org\/10.1016\/S2352-3018(15)00232-5","journal-title":"The Lancet HIV"},{"key":"4421_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08311-0","author":"A Violari","year":"2019","unstructured":"Violari A et al (2019) A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-019-08311-0","journal-title":"Nat Commun"},{"key":"4421_CR179","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078287","author":"W St\u00f6hr","year":"2013","unstructured":"St\u00f6hr W et al (2013) Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0078287","journal-title":"PLoS ONE"},{"key":"4421_CR180","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.03821","volume":"3","author":"JP Williams","year":"2014","unstructured":"Williams JP et al (2014) HIV-1 DNA predicts disease progression and post-treatment virological control. Elife 3:e03821. https:\/\/doi.org\/10.7554\/eLife.03821","journal-title":"Elife"},{"issue":"12","key":"4421_CR181","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","volume":"218","author":"G Namazi","year":"2018","unstructured":"Namazi G et al (2018) The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J Infect Dis 218(12):1954\u20131963. https:\/\/doi.org\/10.1093\/infdis\/jiy479","journal-title":"J Infect Dis"},{"issue":"10","key":"4421_CR182","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/infdis\/jiu297","volume":"210","author":"K Luzuriaga","year":"2014","unstructured":"Luzuriaga K et al (2014) HIV Type 1 (HIV-1) Proviral reservoirs decay continuously under sustained Virologic control in HIV-1-infected children who received early treatment. J Infect Dis 210(10):1529\u20131538. https:\/\/doi.org\/10.1093\/infdis\/jiu297","journal-title":"J Infect Dis"},{"issue":"1","key":"4421_CR183","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/infdis\/jiu827","volume":"212","author":"GU Van Zyl","year":"2015","unstructured":"Van Zyl GU, Bedison MA, Van Rensburg AJ, Laughton B, Cotton MF, Mellors JW (2015) Early antiretroviral therapy in South African children reduces HIV-1-infected cells and cell-associated HIV-1 RNA in blood mononuclear cells. J Infect Dis 212(1):39\u201343. https:\/\/doi.org\/10.1093\/infdis\/jiu827","journal-title":"J Infect Dis"},{"key":"4421_CR184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195514","author":"L Kuhn","year":"2018","unstructured":"Kuhn L et al (2018) Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1infected children. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0195514","journal-title":"PLoS ONE"},{"key":"4421_CR185","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.100241","author":"L Kuhn","year":"2020","unstructured":"Kuhn L et al (2020) Early antiretroviral treatment of infants to attain HIV remission. EClin Med. https:\/\/doi.org\/10.1016\/j.eclinm.2019.100241","journal-title":"EClin Med"},{"key":"4421_CR186","unstructured":"Graziosi C, Soudeyns H, Rizzardi GP, Bart PA, Chapuis A and Pantaleo G (1998) Immunopathogenesis of HIV infection. AIDS Res Hum Retroviruses 14(Suppl 2)"},{"key":"4421_CR187","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1146\/annurev.micro.50.1.825","volume":"50","author":"G Pantaleo","year":"1996","unstructured":"Pantaleo G, Fauci AS (1996) Immunopathogenesis of HIV infection. Ann Rev Microbiol 50:825\u2013854. https:\/\/doi.org\/10.1146\/annurev.micro.50.1.825","journal-title":"Ann Rev Microbiol"},{"issue":"7","key":"4421_CR188","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nm0703-861","volume":"9","author":"NL Letvin","year":"2003","unstructured":"Letvin NL, Walker BD (2003) Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 9(7):861\u2013866","journal-title":"Nat Med"},{"issue":"1","key":"4421_CR189","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1086\/421775","volume":"39","author":"RC Arduino","year":"2004","unstructured":"Arduino RC et al (2004) CD4 cell response to 3 doses of subcutaneous interleukin 2: Meta-analysis of 3 vanguard studies. Clin Infect Dis 39(1):115\u2013122. https:\/\/doi.org\/10.1086\/421775","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4421_CR190","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.aids.0000206504.09159.d3","volume":"20","author":"Y L\u00e9vy","year":"2006","unstructured":"L\u00e9vy Y et al (2006) Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 20(3):405\u2013413. https:\/\/doi.org\/10.1097\/01.aids.0000206504.09159.d3","journal-title":"AIDS"},{"issue":"4","key":"4421_CR191","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/01.aids.0000199827.79983.66","volume":"20","author":"PA Bart","year":"2006","unstructured":"Bart PA, Pantaleo G (2006) Immune-based interventions in HIV infection: doing the right studies, getting the right answers. AIDS 20(4):617\u2013618. https:\/\/doi.org\/10.1097\/01.aids.0000199827.79983.66","journal-title":"AIDS"},{"issue":"5681","key":"4421_CR192","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1126\/science.1100600","volume":"305","author":"B Autran","year":"2004","unstructured":"Autran B, Carcelain G, Combadiere B, Debre P (2004) Therapeutic vaccines for chronic infections. Science 305(5681):205\u2013208. https:\/\/doi.org\/10.1126\/science.1100600","journal-title":"Science"},{"issue":"14","key":"4421_CR193","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1097\/QAD.0b013e32830fbdbc","volume":"22","author":"V Avettand-Fenoel","year":"2008","unstructured":"Avettand-Fenoel V et al (2008) HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressors. AIDS 22(14):1880\u20131882. https:\/\/doi.org\/10.1097\/QAD.0b013e32830fbdbc","journal-title":"AIDS"},{"issue":"6193","key":"4421_CR194","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1126\/science.1255512","volume":"345","author":"DH Barouch","year":"2014","unstructured":"Barouch DH, Deeks SG (2014) Immunologic strategies for HIV-1 remission and eradication. Science 345(6193):169\u2013174. https:\/\/doi.org\/10.1126\/science.1255512 (American Association for the Advancement of Science)","journal-title":"Science"},{"issue":"7534","key":"4421_CR195","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature14053","volume":"517","author":"K Deng","year":"2015","unstructured":"Deng K et al (2015) Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517(7534):381\u2013385. https:\/\/doi.org\/10.1038\/nature14053","journal-title":"Nature"},{"issue":"12","key":"4421_CR196","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","volume":"107","author":"MR Betts","year":"2006","unstructured":"Betts MR et al (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107(12):4781\u20134789. https:\/\/doi.org\/10.1182\/blood-2005-12-4818","journal-title":"Blood"},{"issue":"16","key":"4421_CR197","doi-asserted-by":"publisher","first-page":"8468","DOI":"10.1128\/jvi.00228-07","volume":"81","author":"S Kannanganat","year":"2007","unstructured":"Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR (2007) Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 81(16):8468\u20138476. https:\/\/doi.org\/10.1128\/jvi.00228-07","journal-title":"J Virol"},{"issue":"3","key":"4421_CR198","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.immuni.2012.01.014","volume":"36","author":"L Shan","year":"2012","unstructured":"Shan L et al (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36(3):491\u2013501. https:\/\/doi.org\/10.1016\/j.immuni.2012.01.014","journal-title":"Immunity"},{"issue":"6","key":"4421_CR199","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/J.IMMUNI.2008.10.010","volume":"29","author":"SA Migueles","year":"2008","unstructured":"Migueles SA et al (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29(6):1009. https:\/\/doi.org\/10.1016\/J.IMMUNI.2008.10.010","journal-title":"Immunity"},{"issue":"6128","key":"4421_CR200","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/328345a0","volume":"328","author":"BD Walker","year":"1988","unstructured":"Walker BD et al (1988) HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328(6128):345\u2013348. https:\/\/doi.org\/10.1038\/328345a0","journal-title":"Nature"},{"issue":"7","key":"4421_CR201","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1128\/jvi.68.7.4650-4655.1994","volume":"68","author":"RA Koup","year":"1994","unstructured":"Koup RA et al (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68(7):4650\u20134655. https:\/\/doi.org\/10.1128\/jvi.68.7.4650-4655.1994","journal-title":"J Virol"},{"key":"4421_CR202","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev.med.53.082901.104011","volume":"53","author":"RT Gandhi","year":"2002","unstructured":"Gandhi RT, Walker BD (2002) Immunologic control of HIV-1. Ann Rev Med 53:149\u2013172. https:\/\/doi.org\/10.1146\/annurev.med.53.082901.104011","journal-title":"Ann Rev Med"},{"issue":"3","key":"4421_CR203","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/COH.0b013e3283454c39","volume":"6","author":"AR Hersperger","year":"2011","unstructured":"Hersperger AR, Migueles SA, Betts MR, Connors M (2011) Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS 6(3):169\u2013173. https:\/\/doi.org\/10.1097\/COH.0b013e3283454c39","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"4421_CR204","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/imr.12823","volume":"292","author":"C Fenwick","year":"2019","unstructured":"Fenwick C et al (2019) T-cell exhaustion in HIV infection. Immunol Rev 292(1):149\u2013163. https:\/\/doi.org\/10.1111\/imr.12823 (Blackwell Publishing Ltd)","journal-title":"Immunol Rev"},{"key":"4421_CR205","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3389\/fimmu.2019.02109","volume":"10","author":"G Mylvaganam","year":"2019","unstructured":"Mylvaganam G, Yanez AG, Maus M, Walker BD (2019) Toward T cell-mediated control or elimination of HIV reservoirs: lessons from cancer immunology. Front Immunol 10:2109. https:\/\/doi.org\/10.3389\/fimmu.2019.02109","journal-title":"Front Immunol"},{"issue":"9","key":"4421_CR206","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.1128\/jvi.73.9.7108-7116.1999","volume":"73","author":"M Dalod","year":"1999","unstructured":"Dalod M et al (1999) Broad, intense anti-Human Immunodeficiency Virus (HIV) ex vivo CD8+ responses in HIV Type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol 73(9):7108\u20137116. https:\/\/doi.org\/10.1128\/jvi.73.9.7108-7116.1999","journal-title":"J Virol"},{"issue":"3","key":"4421_CR207","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1128\/jvi.77.3.2081-2092.2003","volume":"77","author":"MM Addo","year":"2003","unstructured":"Addo MM et al (2003) Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77(3):2081\u20132092. https:\/\/doi.org\/10.1128\/jvi.77.3.2081-2092.2003","journal-title":"J Virol"},{"issue":"4","key":"4421_CR208","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1086\/432002","volume":"192","author":"S Kinloch-De Loes","year":"2005","unstructured":"Kinloch-De Loes S et al (2005) Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 192(4):607\u2013617. https:\/\/doi.org\/10.1086\/432002","journal-title":"J Infect Dis"},{"issue":"11","key":"4421_CR209","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1097\/QAD.0b013e3282fdce94","volume":"22","author":"B Autran","year":"2008","unstructured":"Autran B et al (2008) Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 22(11):1313\u20131322. https:\/\/doi.org\/10.1097\/QAD.0b013e3282fdce94","journal-title":"AIDS"},{"key":"4421_CR210","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004682","author":"F Garc\u00eda","year":"2013","unstructured":"Garc\u00eda F et al (2013) A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3004682","journal-title":"Sci Transl Med"},{"issue":"4","key":"4421_CR211","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1473-3099(13)70343-8","volume":"14","author":"RB Pollard","year":"2014","unstructured":"Pollard RB et al (2014) Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 14(4):291\u2013300. https:\/\/doi.org\/10.1016\/S1473-3099(13)70343-8","journal-title":"Lancet Infect Dis"},{"issue":"6091","key":"4421_CR212","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1126\/science.1225416","volume":"337","author":"DR Burton","year":"2012","unstructured":"Burton DR, Poignard P, Stanfield RL, Wilson IA (2012) Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337(6091):183\u2013186. https:\/\/doi.org\/10.1126\/science.1225416 (American Association for the Advancement of Science)","journal-title":"Science"},{"issue":"7475","key":"4421_CR213","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch DH et al (2013) Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503(7475):224\u2013228. https:\/\/doi.org\/10.1038\/nature12744","journal-title":"Nature"},{"issue":"5","key":"4421_CR214","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","volume":"158","author":"A Halper-Stromberg","year":"2014","unstructured":"Halper-Stromberg A et al (2014) Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158(5):989\u2013999. https:\/\/doi.org\/10.1016\/j.cell.2014.07.043","journal-title":"Cell"},{"issue":"7427","key":"4421_CR215","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature11604","volume":"492","author":"F Klein","year":"2012","unstructured":"Klein F et al (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427):118\u2013122. https:\/\/doi.org\/10.1038\/nature11604","journal-title":"Nature"},{"issue":"7475","key":"4421_CR216","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature12746","volume":"503","author":"M Shingai","year":"2013","unstructured":"Shingai M et al (2013) Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503(7475):277\u2013280. https:\/\/doi.org\/10.1038\/nature12746","journal-title":"Nature"},{"issue":"1","key":"4421_CR217","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S2352-3018(14)70014-1","volume":"1","author":"TA Rasmussen","year":"2014","unstructured":"Rasmussen TA et al (2014) Panobinostat, a histone deacetylase inhibitor, for latent virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1\/2, single group, clinical trial. The Lancet HIV 1(1):e13\u2013e21. https:\/\/doi.org\/10.1016\/S2352-3018(14)70014-1","journal-title":"The Lancet HIV"},{"key":"4421_CR218","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.712122","author":"SR Walsh","year":"2021","unstructured":"Walsh SR, Seaman MS (2021) Broadly Neutralizing Antibodies for HIV-1 Prevention. Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2021.712122","journal-title":"Front Immunol"},{"key":"4421_CR219","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev-med-061016-041032","volume":"69","author":"L Gama","year":"2018","unstructured":"Gama L, Koup RA (2018) New-generation high-potency and designer antibodies: role in HIV-1 treatment. Ann Rev Med 69:409\u2013419. https:\/\/doi.org\/10.1146\/annurev-med-061016-041032 (Annual Reviews Inc.)","journal-title":"Ann Rev Med"},{"issue":"7","key":"4421_CR220","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1128\/jvi.67.7.3978-3988.1993","volume":"67","author":"M Thali","year":"1993","unstructured":"Thali M et al (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67(7):3978\u20133988. https:\/\/doi.org\/10.1128\/jvi.67.7.3978-3988.1993","journal-title":"J Virol"},{"issue":"22","key":"4421_CR221","doi-asserted-by":"publisher","first-page":"10892","DOI":"10.1128\/jvi.75.22.10892-10905.2001","volume":"75","author":"MB Zwick","year":"2001","unstructured":"Zwick MB et al (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75(22):10892\u201310905. https:\/\/doi.org\/10.1128\/jvi.75.22.10892-10905.2001","journal-title":"J Virol"},{"issue":"26","key":"4421_CR222","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1073\/pnas.1309215110","volume":"110","author":"AP West","year":"2013","unstructured":"West AP, Scharf L, Horwitz J, Klein F, Nussenzweig MC, Bjorkman PJ (2013) Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc Natl Acad Sci USA 110(26):10598\u201310603. https:\/\/doi.org\/10.1073\/pnas.1309215110","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"4421_CR223","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","volume":"9","author":"Y Liu","year":"2020","unstructured":"Liu Y, Cao W, Sun M, Li T (2020) Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microb Infect 9(1):194\u2013206. https:\/\/doi.org\/10.1080\/22221751.2020.1713707 (Taylor and Francis Ltd)","journal-title":"Emerg Microb Infect"},{"issue":"1","key":"4421_CR224","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11684-019-0721-9","volume":"14","author":"Q Wang","year":"2020","unstructured":"Wang Q, Zhang L (2020) Broadly neutralizing antibodies and vaccine design against HIV-1 infection. Front Med 14(1):30\u201342. https:\/\/doi.org\/10.1007\/s11684-019-0721-9 (Higher Education Press)","journal-title":"Front Med"},{"issue":"7601","key":"4421_CR225","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/NATURE17677","volume":"533","author":"R Gautam","year":"2016","unstructured":"Gautam R et al (2016) A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533(7601):105\u2013109. https:\/\/doi.org\/10.1038\/NATURE17677","journal-title":"Nature"},{"key":"4421_CR226","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.3008992","author":"A Pegu","year":"2014","unstructured":"Pegu A et al (2014) Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3008992","journal-title":"Sci Transl Med"},{"key":"4421_CR227","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01187-17","author":"B Julg","year":"2017","unstructured":"Julg B et al (2017) Protective efficacy of broadly neutralizing antibodies with incomplete neutralization activity against simian-human immunodeficiency virus in rhesus monkeys. J Virol. https:\/\/doi.org\/10.1128\/JVI.01187-17","journal-title":"J Virol"},{"key":"4421_CR228","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAL1321","author":"B Julg","year":"2017","unstructured":"Julg B et al (2017) Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAL1321","journal-title":"Sci Transl Med"},{"issue":"4","key":"4421_CR229","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41591-019-0412-8","volume":"25","author":"M Caskey","year":"2019","unstructured":"Caskey M, Klein F, Nussenzweig MC (2019) Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med 25(4):547\u2013553. https:\/\/doi.org\/10.1038\/s41591-019-0412-8","journal-title":"Nat Med"},{"issue":"7557","key":"4421_CR230","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey M et al (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522(7557):487\u2013491. https:\/\/doi.org\/10.1038\/nature14411","journal-title":"Nature"},{"key":"4421_CR231","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5752","author":"RM Lynch","year":"2015","unstructured":"Lynch RM et al (2015) Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aad5752","journal-title":"Sci Transl Med"},{"issue":"7613","key":"4421_CR232","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid JF et al (2016) HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535(7613):556\u2013560. https:\/\/doi.org\/10.1038\/nature18929","journal-title":"Nature"},{"issue":"7724","key":"4421_CR233","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza P et al (2018) Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561(7724):479\u2013484. https:\/\/doi.org\/10.1038\/s41586-018-0531-2","journal-title":"Nature"},{"key":"4421_CR234","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.710044\/FULL","author":"DC Hsu","year":"2021","unstructured":"Hsu DC, Mellors JW, Vasan S (2021) Can broadly neutralizing HIV-1 antibodies help achieve an ART-free remission? Front Immunol. https:\/\/doi.org\/10.3389\/FIMMU.2021.710044\/FULL","journal-title":"Front Immunol"},{"issue":"5","key":"4421_CR235","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/J.APSB.2020.10.020","volume":"11","author":"H Dana","year":"2021","unstructured":"Dana H et al (2021) CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharmaceutica Sinica B 11(5):1129\u20131147. https:\/\/doi.org\/10.1016\/J.APSB.2020.10.020","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"4421_CR236","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5474602","author":"H Alm\u00e5sbak","year":"2016","unstructured":"Alm\u00e5sbak H, Aarvak T, Vemuri MC (2016) CAR T cell therapy: a game changer in cancer treatment. J Immunol Res. https:\/\/doi.org\/10.1155\/2016\/5474602","journal-title":"J Immunol Res"},{"issue":"1","key":"4421_CR237","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","volume":"19","author":"A Miliotou","year":"2018","unstructured":"Miliotou A, Papadopoulou L (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19(1):5\u201318. https:\/\/doi.org\/10.2174\/1389201019666180418095526","journal-title":"Curr Pharm Biotechnol"},{"key":"4421_CR238","doi-asserted-by":"publisher","DOI":"10.3389\/FCIMB.2020.00410","author":"W Mu","year":"2020","unstructured":"Mu W, Carrillo MA, Kitchen SG (2020) Engineering CAR T cells to target the HIV reservoir. Front Cell Infect Microbiol. https:\/\/doi.org\/10.3389\/FCIMB.2020.00410","journal-title":"Front Cell Infect Microbiol"},{"key":"4421_CR239","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/J.OMTM.2018.12.009","volume":"12","author":"S Guedan","year":"2018","unstructured":"Guedan S, Calderon H, Posey A, Maus M (2018) Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev 12:145\u2013156. https:\/\/doi.org\/10.1016\/J.OMTM.2018.12.009","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"4421_CR240","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/14653240310001488","volume":"5","author":"M Pule","year":"2003","unstructured":"Pule M, Finney H, Lawson A (2003) Artificial T-cell receptors. Cytotherapy 5(3):211\u2013226. https:\/\/doi.org\/10.1080\/14653240310001488","journal-title":"Cytotherapy"},{"issue":"8","key":"4421_CR241","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H (2015) TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15(8):1145\u20131154. https:\/\/doi.org\/10.1517\/14712598.2015.1046430","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"4421_CR242","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/IMR.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H (2014) Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 257(1):83\u201390. https:\/\/doi.org\/10.1111\/IMR.12125","journal-title":"Immunol Rev"},{"issue":"48","key":"4421_CR243","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/PNAS.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV et al (2016) Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci 113(48):E7788\u2013E7797. https:\/\/doi.org\/10.1073\/PNAS.1610544113","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"4421_CR244","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/NBT0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens R, Gunset G, Rivi\u00e8re I, Sadelain M (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol 20(1):70\u201375. https:\/\/doi.org\/10.1038\/NBT0102-70","journal-title":"Nat Biotechnol"},{"issue":"5","key":"4421_CR245","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor\u2013modified T cells in lymphoma patients. J Clin Investig 121(5):1822\u20131826. https:\/\/doi.org\/10.1172\/JCI46110","journal-title":"J Clin Investig"},{"issue":"7","key":"4421_CR246","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/JNCI\/DJY193","volume":"111","author":"RR Sarkar","year":"2019","unstructured":"Sarkar RR, Gloude NJ, Schiff D, Murphy JD (2019) Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia. J Natl Cancer Inst 111(7):719\u2013726. https:\/\/doi.org\/10.1093\/JNCI\/DJY193","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4421_CR247","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874613601610010034","volume":"10","author":"ABM Kharsany","year":"2016","unstructured":"Kharsany ABM, Karim QA (2016) HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J 10(1):34\u201348. https:\/\/doi.org\/10.2174\/1874613601610010034","journal-title":"Open AIDS J"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-022-04421-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-022-04421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:41:25Z","timestamp":1676076085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-022-04421-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":247,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4421"],"URL":"https:\/\/doi.org\/10.1007\/s00018-022-04421-z","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the writing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"400"}}